annual CFF:
-$218.86M+$189.13M(+46.36%)Summary
- As of today (June 22, 2025), HALO annual cash flow from financing activities is -$218.86 million, with the most recent change of +$189.13 million (+46.36%) on December 31, 2024.
- During the last 3 years, HALO annual CFF has fallen by -$296.73 million (-381.08%).
- HALO annual CFF is now -160.40% below its all-time high of $362.37 million, reached on December 31, 2022.
Performance
HALO Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$3.32M+$243.09M(+98.65%)Summary
- As of today (June 22, 2025), HALO quarterly cash flow from financing activities is -$3.32 million, with the most recent change of +$243.09 million (+98.65%) on March 31, 2025.
- Over the past year, HALO quarterly CFF has dropped by -$2.83 million (-579.14%).
- HALO quarterly CFF is now -100.90% below its all-time high of $367.82 million, reached on June 30, 2022.
Performance
HALO quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$221.69M-$2.83M(-1.29%)Summary
- As of today (June 22, 2025), HALO TTM cash flow from financing activities is -$221.69 million, with the most recent change of -$2.83 million (-1.29%) on March 31, 2025.
- Over the past year, HALO TTM CFF has increased by +$22.17 million (+9.09%).
- HALO TTM CFF is now -161.18% below its all-time high of $362.37 million, reached on December 31, 2022.
Performance
HALO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
HALO Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.4% | -579.1% | +9.1% |
| 3 y3 years | -381.1% | -632.2% | +14.8% |
| 5 y5 years | -242.8% | +93.2% | -275.5% |
HALO Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -160.4% | +46.4% | -100.9% | +98.7% | -161.2% | +45.7% |
| 5 y | 5-year | -160.4% | +46.4% | -100.9% | +98.7% | -161.2% | +45.7% |
| alltime | all time | -160.4% | +46.4% | -100.9% | +98.7% | -161.2% | +45.7% |
HALO Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$3.32M(-98.7%) | -$221.69M(+1.3%) |
| Dec 2024 | -$218.86M(-46.4%) | -$246.41M(-1427.6%) | -$218.86M(-1.6%) |
| Sep 2024 | - | $18.56M(+95.7%) | -$222.37M(-6.1%) |
| Jun 2024 | - | $9.48M(-2039.1%) | -$236.83M(-2.9%) |
| Mar 2024 | - | -$489.00K(-99.8%) | -$243.86M(-40.2%) |
| Dec 2023 | -$407.99M(-212.6%) | -$249.92M(-6194.1%) | -$407.99M(+168.9%) |
| Sep 2023 | - | $4.10M(+67.7%) | -$151.74M(-9.8%) |
| Jun 2023 | - | $2.45M(-101.5%) | -$168.24M(-185.3%) |
| Mar 2023 | - | -$164.61M(-2700.9%) | $197.13M(-45.6%) |
| Dec 2022 | $362.37M(+365.4%) | $6.33M(-151.0%) | $362.37M(+81.2%) |
| Sep 2022 | - | -$12.40M(-103.4%) | $200.03M(+31.3%) |
| Jun 2022 | - | $367.82M(>+9900.0%) | $152.36M(-158.6%) |
| Mar 2022 | - | $624.00K(-100.4%) | -$260.21M(-434.2%) |
| Dec 2021 | $77.86M(-173.3%) | -$156.01M(+159.7%) | $77.86M(-62.3%) |
| Sep 2021 | - | -$60.07M(+34.2%) | $206.48M(-7.3%) |
| Jun 2021 | - | -$44.76M(-113.2%) | $222.69M(-20.8%) |
| Mar 2021 | - | $338.70M(-1336.2%) | $281.04M(-364.4%) |
| Dec 2020 | -$106.28M(-169.4%) | -$27.40M(-37.5%) | -$106.28M(-180.8%) |
| Sep 2020 | - | -$43.85M(-422.6%) | $131.53M(-15.8%) |
| Jun 2020 | - | $13.59M(-128.0%) | $156.14M(+23.6%) |
| Mar 2020 | - | -$48.62M(-123.1%) | $126.32M(-17.6%) |
| Dec 2019 | $153.22M(-340.2%) | $210.42M(-1193.1%) | $153.22M(-302.8%) |
| Sep 2019 | - | -$19.25M(+18.6%) | -$75.56M(+3.9%) |
| Jun 2019 | - | -$16.23M(-25.3%) | -$72.73M(-0.2%) |
| Mar 2019 | - | -$21.73M(+18.4%) | -$72.88M(+14.2%) |
| Dec 2018 | -$63.80M(-148.5%) | -$18.35M(+11.8%) | -$63.80M(+40.6%) |
| Sep 2018 | - | -$16.42M(+0.3%) | -$45.36M(+52.0%) |
| Jun 2018 | - | -$16.37M(+29.4%) | -$29.83M(-124.4%) |
| Mar 2018 | - | -$12.65M(<-9900.0%) | $122.39M(-7.0%) |
| Dec 2017 | $131.66M(-12.6%) | $82.00K(-109.2%) | $131.66M(-0.1%) |
| Sep 2017 | - | -$890.00K(-100.7%) | $131.85M(-1.0%) |
| Jun 2017 | - | $135.84M(-4116.7%) | $133.22M(+4669.7%) |
| Mar 2017 | - | -$3.38M(-1312.2%) | $2.79M(-98.1%) |
| Dec 2016 | $150.62M(+1050.0%) | $279.00K(-41.4%) | $150.62M(-1.0%) |
| Sep 2016 | - | $476.00K(-91.2%) | $152.07M(+0.0%) |
| Jun 2016 | - | $5.42M(-96.2%) | $152.03M(+1.1%) |
| Mar 2016 | - | $144.45M(+8244.7%) | $150.39M(+1048.2%) |
| Dec 2015 | $13.10M(-88.6%) | $1.73M(+296.1%) | $13.10M(-5.3%) |
| Sep 2015 | - | $437.00K(-88.4%) | $13.84M(-2.5%) |
| Jun 2015 | - | $3.77M(-47.3%) | $14.20M(+22.1%) |
| Mar 2015 | - | $7.16M(+189.6%) | $11.62M(-89.8%) |
| Dec 2014 | $114.50M(+356.8%) | $2.47M(+210.8%) | $114.50M(-15.2%) |
| Sep 2014 | - | $795.00K(-33.8%) | $135.10M(-1.1%) |
| Jun 2014 | - | $1.20M(-98.9%) | $136.61M(+0.9%) |
| Mar 2014 | - | $110.03M(+377.0%) | $135.35M(+440.0%) |
| Dec 2013 | $25.06M | $23.07M(+901.7%) | $25.06M(-21.0%) |
| Sep 2013 | - | $2.30M(-4287.3%) | $31.74M(+7.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$55.00K(-78.2%) | $29.48M(+0.1%) |
| Mar 2013 | - | -$252.00K(-100.8%) | $29.44M(-73.9%) |
| Dec 2012 | $112.82M(+2275.8%) | $29.74M(>+9900.0%) | $112.82M(+34.8%) |
| Sep 2012 | - | $38.90K(-143.2%) | $83.68M(-0.8%) |
| Jun 2012 | - | -$90.00K(-100.1%) | $84.34M(-1.9%) |
| Mar 2012 | - | $83.12M(>+9900.0%) | $86.00M(+1711.2%) |
| Dec 2011 | $4.75M(-92.3%) | $607.00K(-12.7%) | $4.75M(-9.8%) |
| Sep 2011 | - | $695.10K(-56.0%) | $5.26M(-91.9%) |
| Jun 2011 | - | $1.58M(-15.5%) | $64.77M(+2.4%) |
| Mar 2011 | - | $1.87M(+66.7%) | $63.23M(+2.3%) |
| Dec 2010 | $61.82M(+36.3%) | $1.12M(-98.1%) | $61.82M(-0.4%) |
| Sep 2010 | - | $60.20M(>+9900.0%) | $62.06M(+1170.2%) |
| Jun 2010 | - | $34.00K(-92.7%) | $4.89M(-88.7%) |
| Mar 2010 | - | $463.50K(-65.9%) | $43.37M(-4.4%) |
| Dec 2009 | $45.36M(+1664.6%) | $1.36M(-55.1%) | $45.36M(+1.9%) |
| Sep 2009 | - | $3.03M(-92.1%) | $44.51M(+4.4%) |
| Jun 2009 | - | $38.52M(+1473.9%) | $42.63M(+863.5%) |
| Mar 2009 | - | $2.45M(+375.6%) | $4.42M(+72.1%) |
| Dec 2008 | $2.57M(-95.4%) | $514.60K(-55.0%) | $2.57M(-9.1%) |
| Sep 2008 | - | $1.14M(+258.2%) | $2.83M(+32.2%) |
| Jun 2008 | - | $319.10K(-46.2%) | $2.14M(-94.0%) |
| Mar 2008 | - | $593.60K(-23.2%) | $35.83M(-36.0%) |
| Dec 2007 | $56.00M(+205.3%) | $772.50K(+70.3%) | $56.00M(-16.8%) |
| Sep 2007 | - | $453.70K(-98.7%) | $67.27M(-4.9%) |
| Jun 2007 | - | $34.01M(+63.8%) | $70.77M(+87.1%) |
| Mar 2007 | - | $20.76M(+72.4%) | $37.83M(+106.2%) |
| Dec 2006 | $18.34M(+11.4%) | $12.04M(+204.4%) | $18.34M(-18.1%) |
| Sep 2006 | - | $3.96M(+271.1%) | $22.41M(+21.1%) |
| Jun 2006 | - | $1.07M(-16.7%) | $18.50M(+6.1%) |
| Mar 2006 | - | $1.28M(-92.1%) | $17.44M(+5.9%) |
| Dec 2005 | $16.47M(-29.8%) | $16.11M(>+9900.0%) | $16.47M(+4.2%) |
| Sep 2005 | - | $51.30K(+1952.0%) | $15.82M(-0.3%) |
| Jun 2005 | - | $2500.00(-99.2%) | $15.86M(-0.2%) |
| Mar 2005 | - | $310.70K(-98.0%) | $15.89M(-32.2%) |
| Dec 2004 | $23.45M(>+9900.0%) | $15.45M(>+9900.0%) | $23.45M(+231.4%) |
| Sep 2004 | - | $99.00K(+230.0%) | $7.08M(+1.0%) |
| Jun 2004 | - | $30.00K(-99.6%) | $7.01M(-5.8%) |
| Mar 2004 | - | $7.87M(-951.8%) | $7.44M(<-9900.0%) |
| Dec 2003 | $0.00(-100.0%) | -$923.90K(-3190.0%) | -$100.00(-100.0%) |
| Sep 2003 | - | $29.90K(-93.5%) | $923.80K(+3.3%) |
| Jun 2003 | - | $459.50K(+5.8%) | $893.90K(+59.3%) |
| Mar 2003 | - | $434.40K(>+9900.0%) | $561.30K(+342.3%) |
| Dec 2002 | $126.90K(+109.8%) | $0.00(0.0%) | $126.90K(0.0%) |
| Sep 2002 | - | $0.00(-100.0%) | $126.90K(0.0%) |
| Jun 2002 | - | $126.90K(>+9900.0%) | $126.90K(>+9900.0%) |
| Mar 2002 | - | $0.00 | $0.00 |
| Dec 2001 | $60.50K | - | - |
FAQ
- What is Halozyme Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual CFF year-on-year change?
- What is Halozyme Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly CFF year-on-year change?
- What is Halozyme Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM CFF year-on-year change?
What is Halozyme Therapeutics annual cash flow from financing activities?
The current annual CFF of HALO is -$218.86M
What is the all time high annual CFF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cash flow from financing activities is $362.37M
What is Halozyme Therapeutics annual CFF year-on-year change?
Over the past year, HALO annual cash flow from financing activities has changed by +$189.13M (+46.36%)
What is Halozyme Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of HALO is -$3.32M
What is the all time high quarterly CFF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cash flow from financing activities is $367.82M
What is Halozyme Therapeutics quarterly CFF year-on-year change?
Over the past year, HALO quarterly cash flow from financing activities has changed by -$2.83M (-579.14%)
What is Halozyme Therapeutics TTM cash flow from financing activities?
The current TTM CFF of HALO is -$221.69M
What is the all time high TTM CFF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM cash flow from financing activities is $362.37M
What is Halozyme Therapeutics TTM CFF year-on-year change?
Over the past year, HALO TTM cash flow from financing activities has changed by +$22.17M (+9.09%)